We have detected that you are using some form of ad-blocking or filtering.
Please consider white-listing Labnodes since 1) ad-blockers like uBlock break Labnodes functionality and 2) Labnodes does not serve ads.
In the year 2000, a heptavalent pneumococcal conjugate vaccine (PCV7) was licensed and recommended for routine immunization of infants in the USA. During the following years, a number of studies documented the impact of this immunization program on rates of invasive pneumococcal disease, pneumonia and otitis media. This article aims to summarize current evidence on the population-based impact of this infant immunization program in the USA.
© 2010-2020. All Rights Reserved to Vanderbilt University. Vanderbilt University is committed to principles of equal opportunity and affirmative action.
Released July 13, 2020